Melanoma Outcomes

When facing a melanoma diagnosis, the data matters. Moffitt is dedicated to education and transparency so that each patient may enter treatment with clarity, confidence and trust.

The goal of any cancer treatment is to achieve the most favorable outcome while minimizing side effects and ensuring the best possible quality of life. On average, Moffitt's melanoma treatment outcomes exceed 1.5 times the national average. The graphs below show the proportion of patients who survived one year and a minimum of five years after initial diagnosis, displayed by the stage of disease at diagnosis.

Early stage describes cancer in early stage of growth and may differ between cancer types. Intermediate stage cancers have grown more deeply into nearby tissue and may have spread to lymph nodes but not to other parts of the body. Advanced stage, also called metastatic cancer, means the cancer has spread to other parts of the body. No matter the stage of your cancer, Moffitt Cancer Center can help you improve your prognosis and quality of life.

Learn More About Melanoma Treatment

Cases diagnosed 2012-2018, class of case 10-22

Early, intermediate and advanced stages at diagnosis correspond to localized, regional and distant SEER stages, respectively.

Notes:

  • Survival statistics are expressed as percents.
  • Statistics are based on the November 2021 submission of data from the population-based SEER 17 registries and are based on follow-up of patients into 2019.
  • Statistics are provided by the SEER Program for research purposes only. 
  • Moffitt relative survival rates calculated using CNExT software version 2.0.1.10

Citation:
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2021 Sub (2000-2019) , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2022, based on the November 2021 submission.